Humana
- Home ›
- US ›
- Healthcare
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. The last earnings update was 56 days ago. More info.
Add to Portfolio Compare Print
- Humana has significant price volatility in the past 3 months.
HUM Share Price and Events
7 Day Returns
1 Year Returns
HUM Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Humana (HUM) | -7.7% | -16% | -18.6% | -18.4% | 38.8% | 121.2% |
| US Healthcare | -7.2% | -7.9% | -9.9% | -5.6% | 12.9% | 61.6% |
| US Market | 0.8% | 2.6% | 10.6% | 5.9% | 37.7% | 45.5% |
1 Year Return vs Industry and Market
- HUM underperformed the Healthcare industry which returned -5.6% over the past year.
- HUM underperformed the Market in United States of America which returned 5.9% over the past year.
Price Volatility
Related Companies
Value
Is Humana undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Humana
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Humana.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 15 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 8% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Healthcare Unlevered Beta | Simply Wall St/ S&P Global | 0.72 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.716 (1 + (1- 21%) (19.11%)) |
0.882 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.88 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.882 * 5.96%) |
7.99% |
Discounted Cash Flow Calculation for NYSE:HUM using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Humana is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 7.99%) |
|
|---|---|---|---|
| 2019 | 2,162.25 | Analyst x4 | 2,002.32 |
| 2020 | 2,521.60 | Analyst x5 | 2,162.37 |
| 2021 | 2,960.75 | Analyst x4 | 2,351.16 |
| 2022 | 3,458.00 | Analyst x2 | 2,542.91 |
| 2023 | 3,862.50 | Analyst x2 | 2,630.28 |
| 2024 | 4,193.13 | Est @ 8.56% | 2,644.22 |
| 2025 | 4,478.72 | Est @ 6.81% | 2,615.42 |
| 2026 | 4,728.93 | Est @ 5.59% | 2,557.27 |
| 2027 | 4,952.59 | Est @ 4.73% | 2,480.12 |
| 2028 | 5,157.13 | Est @ 4.13% | 2,391.52 |
| Present value of next 10 years cash flows | $24,377.59 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $5,157.13 × (1 + 2.73%) ÷ (7.99% – 2.73%) |
$100,769.48 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $100,769.48 ÷ (1 + 7.99%)10 |
$46,730.00 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $24,377.59 + $46,730.00 |
$71,107.58 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $71,107.58 / 135.64 |
$524.25 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $524.25 |
| Current discount | Discount to share price of
$240.69
= -1 x ($240.69 - $524.25) / $524.25 |
54.1% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Humana's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Humana's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Humana's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Humana's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in USD | $12.24 |
| NYSE:HUM Share Price ** | NYSE (2019-04-18) in USD | $240.69 |
| United States of America Healthcare Industry PE Ratio | Median Figure of 53 Publicly-Listed Healthcare Companies | 21.71x |
| United States of America Market PE Ratio | Median Figure of 3,078 Publicly-Listed Companies | 18.23x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Humana.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NYSE:HUM Share Price ÷ EPS (both in USD) = 240.69 ÷ 12.24 |
19.66x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Humana is good value based on earnings compared to the US Healthcare industry average.
- Humana is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does
Humana's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 19.66x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts |
14.3%per year |
| United States of America Healthcare Industry PEG Ratio | Median Figure of 40 Publicly-Listed Healthcare Companies | 1.5x |
| United States of America Market PEG Ratio | Median Figure of 2,108 Publicly-Listed Companies | 1.56x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 19.66x ÷ 14.3% |
1.37x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Humana is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
Humana's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in USD | $74.95 |
| NYSE:HUM Share Price * | NYSE (2019-04-18) in USD | $240.69 |
| United States of America Healthcare Industry PB Ratio | Median Figure of 93 Publicly-Listed Healthcare Companies | 2.32x |
| United States of America Market PB Ratio | Median Figure of 5,172 Publicly-Listed Companies | 1.93x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NYSE:HUM Share Price ÷ Book Value per Share (both in USD) = 240.69 ÷ 74.95 |
3.21x |
* Primary Listing of Humana.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Humana is overvalued based on assets compared to the US Healthcare industry average.
Value checks
We assess Humana's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check) Humana has a total score of 3/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
How is Humana expected to perform in the next 1 to 3 years based on estimates from 15 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Humana's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- Humana's earnings growth is expected to exceed the United States of America market average.
- Humana's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NYSE:HUM Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts | 14.3% |
| NYSE:HUM Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 15 Analysts | 8.7% |
| United States of America Healthcare Industry Earnings Growth Rate | Market Cap Weighted Average | 13.2% |
| United States of America Healthcare Industry Revenue Growth Rate | Market Cap Weighted Average | 7.2% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.3% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 15 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 5,506 | 3,773 | ||
| 2022-12-31 | 4,858 | 3,319 | ||
| 2021-12-31 | 74,051 | 3,612 | 2,829 | 5 |
| 2020-12-31 | 68,736 | 3,258 | 2,519 | 10 |
| 2019-12-31 | 63,179 | 2,812 | 2,298 | 10 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 56,912 | 2,173 | 1,683 |
| 2018-09-30 | 55,933 | -405 | 1,512 |
| 2018-06-30 | 55,009 | 3,513 | 1,367 |
| 2018-03-31 | 54,284 | 3,532 | 1,824 |
| 2017-12-31 | 53,767 | 4,051 | 2,448 |
| 2017-09-30 | 53,456 | 4,189 | 1,863 |
| 2017-06-30 | 53,868 | 5,829 | 1,814 |
| 2017-03-31 | 54,341 | 5,639 | 1,475 |
| 2016-12-31 | 54,379 | 1,936 | 614 |
| 2016-09-30 | 54,862 | 5,046 | 1,116 |
| 2016-06-30 | 54,531 | 1,575 | 980 |
| 2016-03-31 | 54,256 | 1,263 | 1,100 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 15 Analyst Estimates (S&P Global) | See Below |
All data from Humana Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 28.13 | 28.13 | 28.13 | 1.00 |
| 2022-12-31 | 24.63 | 24.63 | 24.63 | 1.00 |
| 2021-12-31 | 21.64 | 22.20 | 21.16 | 3.00 |
| 2020-12-31 | 18.91 | 20.04 | 18.27 | 10.00 |
| 2019-12-31 | 16.98 | 17.39 | 16.28 | 10.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-12-31 | 12.24 |
| 2018-09-30 | 10.90 |
| 2018-06-30 | 9.74 |
| 2018-03-31 | 12.84 |
| 2017-12-31 | 16.94 |
| 2017-09-30 | 12.71 |
| 2017-06-30 | 12.27 |
| 2017-03-31 | 9.90 |
| 2016-12-31 | 4.11 |
| 2016-09-30 | 7.48 |
| 2016-06-30 | 6.57 |
| 2016-03-31 | 7.38 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Humana's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Humana has a total score of 3/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Humana performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Humana's year on year earnings growth rate has been positive over the past 5 years.
- Humana's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Humana's 1-year earnings growth is negative, it can't be compared to the US Healthcare industry average.
Earnings and Revenue History
All data from Humana Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 56,912.00 | 1,683.00 | 7,525.00 | |
| 2018-09-30 | 55,933.00 | 1,512.00 | 7,135.00 | |
| 2018-06-30 | 55,009.00 | 1,367.00 | 6,923.00 | |
| 2018-03-31 | 54,284.00 | 1,824.00 | 6,615.00 | |
| 2017-12-31 | 53,767.00 | 2,448.00 | 6,419.00 | |
| 2017-09-30 | 53,456.00 | 1,863.00 | 6,695.00 | |
| 2017-06-30 | 53,868.00 | 1,814.00 | 6,746.00 | |
| 2017-03-31 | 54,341.00 | 1,475.00 | 6,992.00 | |
| 2016-12-31 | 54,379.00 | 614.00 | 7,173.00 | |
| 2016-09-30 | 54,862.00 | 1,116.00 | 7,028.00 | |
| 2016-06-30 | 54,531.00 | 980.00 | 6,966.00 | |
| 2016-03-31 | 54,256.00 | 1,100.00 | 7,084.00 | |
| 2015-12-31 | 54,289.00 | 1,276.00 | 7,295.00 | |
| 2015-09-30 | 53,256.00 | 1,320.00 | 7,560.00 | |
| 2015-06-30 | 52,131.00 | 1,296.00 | 7,781.00 | |
| 2015-03-31 | 50,621.00 | 1,209.00 | 7,799.00 | |
| 2014-12-31 | 48,500.00 | 1,147.00 | 7,639.00 | |
| 2014-09-30 | 46,359.00 | 972.00 | 7,426.00 | |
| 2014-06-30 | 44,440.00 | 1,050.00 | 7,068.00 | |
| 2014-03-31 | 42,539.00 | 1,126.00 | 6,694.00 | |
| 2013-12-31 | 41,313.00 | 1,231.00 | 6,355.00 | |
| 2013-09-30 | 40,683.00 | 1,453.00 | 6,102.00 | |
| 2013-06-30 | 40,015.00 | 1,511.00 | 5,970.00 | |
| 2013-03-31 | 39,393.00 | 1,447.00 | 5,893.00 | |
| 2012-12-31 | 39,126.00 | 1,222.00 | 5,830.00 | |
| 2012-09-30 | 38,625.00 | 1,229.00 | 5,760.00 | |
| 2012-06-30 | 38,275.00 | 1,248.00 | 5,713.00 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Humana has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Humana used its assets more efficiently than the US Healthcare industry average last year based on Return on Assets.
- Humana has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess Humana's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Humana has a total score of 3/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Humana's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Humana's finances.
The net worth of a company is the difference between its assets and liabilities.
- Humana is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Humana's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 2.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Humana Company Filings, last reported 3 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 10,161.00 | 6,240.00 | 12,369.00 |
| 2018-09-30 | 10,593.00 | 5,371.00 | 13,837.00 |
| 2018-06-30 | 10,211.00 | 5,245.00 | 17,516.00 |
| 2018-03-31 | 10,081.00 | 5,294.00 | 18,597.00 |
| 2017-12-31 | 9,842.00 | 5,061.00 | 13,599.00 |
| 2017-09-30 | 11,211.00 | 5,101.00 | 18,487.00 |
| 2017-06-30 | 10,953.00 | 5,097.00 | 16,254.00 |
| 2017-03-31 | 10,234.00 | 5,428.00 | 16,630.00 |
| 2016-12-31 | 10,685.00 | 4,304.00 | 11,472.00 |
| 2016-09-30 | 11,285.00 | 4,275.00 | 14,098.00 |
| 2016-06-30 | 10,874.00 | 4,285.00 | 9,846.00 |
| 2016-03-31 | 10,525.00 | 4,350.00 | 10,539.00 |
| 2015-12-31 | 10,346.00 | 4,394.00 | 9,838.00 |
| 2015-09-30 | 10,353.00 | 4,129.00 | 9,020.00 |
| 2015-06-30 | 10,083.00 | 4,432.00 | 9,291.00 |
| 2015-03-31 | 10,044.00 | 4,112.00 | 9,546.00 |
| 2014-12-31 | 9,646.00 | 4,159.00 | 9,533.00 |
| 2014-09-30 | 10,125.00 | 4,605.00 | 10,793.00 |
| 2014-06-30 | 10,000.00 | 2,889.00 | 9,158.00 |
| 2014-03-31 | 9,725.00 | 2,865.00 | 9,910.00 |
| 2013-12-31 | 9,316.00 | 3,003.00 | 9,228.00 |
| 2013-09-30 | 9,606.00 | 2,876.00 | 9,517.00 |
| 2013-06-30 | 9,335.00 | 2,852.00 | 9,075.00 |
| 2013-03-31 | 9,164.00 | 2,898.00 | 9,539.00 |
| 2012-12-31 | 8,847.00 | 2,935.00 | 9,307.00 |
| 2012-09-30 | 8,691.00 | 1,893.00 | 9,421.00 |
| 2012-06-30 | 8,455.00 | 1,878.00 | 11,751.00 |
- Humana's level of debt (61.4%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (32.2% vs 61.4% today).
- Debt is well covered by operating cash flow (34.8%, greater than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 14.3x coverage).
Financial health checks
We assess Humana's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Humana has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Humana's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Humana
shares you are expected to receive
$18
in your first year as a dividend.
Dividend Amount
- Humana's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.4%).
- Humana's dividend is below the markets top 25% of dividend payers in United States of America (3.63%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 15 Analyst Estimates (S&P Global) | See Below |
| United States of America Healthcare Industry Average Dividend Yield | Market Cap Weighted Average of 21 Stocks | 1.6% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2009 Stocks | 2.4% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.6% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | 2.45 | 5.00 |
| 2020-12-31 | 2.29 | 8.00 |
| 2019-12-31 | 2.11 | 8.00 |
| Date (Data in $) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2019-02-21 | 2.200 | 0.806 |
| 2019-02-06 | 2.200 | 0.727 |
| 2018-11-02 | 2.000 | 0.661 |
| 2018-08-16 | 2.000 | 0.606 |
| 2018-04-19 | 2.000 | 0.660 |
| 2018-02-16 | 2.000 | 0.726 |
| 2018-02-07 | 2.000 | 0.751 |
| 2017-11-02 | 1.600 | 0.624 |
| 2017-08-17 | 1.600 | 0.645 |
| 2017-04-20 | 1.600 | 0.684 |
| 2017-02-14 | 1.600 | 0.757 |
| 2016-10-26 | 1.160 | 0.586 |
| 2016-08-25 | 1.160 | 0.660 |
| 2016-04-21 | 1.160 | 0.662 |
| 2016-02-18 | 1.160 | 0.650 |
| 2015-10-29 | 1.160 | 0.681 |
| 2015-08-27 | 1.160 | 0.638 |
| 2015-04-17 | 1.160 | 0.624 |
| 2015-02-18 | 1.120 | 0.657 |
| 2014-10-31 | 1.120 | 0.778 |
| 2014-08-27 | 1.120 | 0.862 |
| 2014-04-30 | 1.120 | 0.907 |
| 2014-02-19 | 1.080 | 0.976 |
| 2013-10-30 | 1.080 | 1.092 |
| 2013-08-22 | 1.080 | 1.143 |
| 2013-04-25 | 1.080 | 1.289 |
| 2013-02-27 | 1.040 | 1.451 |
| 2012-10-18 | 1.040 | 1.472 |
| 2012-08-24 | 1.040 | 1.452 |
| 2012-04-30 | 1.040 | 1.401 |
| 2012-02-24 | 1.000 | 1.136 |
| 2011-10-24 | 1.000 | 1.144 |
| 2011-08-19 | 1.000 | 1.345 |
| 2011-04-26 | 1.000 | 1.289 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Whilst dividend payments have been stable, Humana has been paying a dividend for less than 10 years.
- Dividend payments have increased, but Humana only paid a dividend in the past 8 years.
Income/ dividend checks
We assess Humana's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Humana afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Humana has a total score of 2/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $16,312,517 |
| AGE | 56 |
| TENURE AS CEO | 6.3 years |
CEO Bio
Mr. Bruce Dale Broussard serves as the Member of Advisory Board of HealthQuest Capital. Mr. Bruce serves as the Member of Advisory Board at Flare Capital Management Company, LLC. Mr. Broussard has been the Chief Executive Officer and President of Humana Inc. since January 01, 2013. He serves as Chief Executive Officer, President, and Director at Humana Insurance Company. Under his leadership, Humana is creating an integrated care delivery model that is expected to drive lower costs, enhanced quality, improved outcomes and a better member experience. Prior to joining Humana, Mr. Broussard served as the Chief Executive Officer of McKesson Specialty/US Oncology, Inc. He served as the President of US Oncology Holdings Inc. since November 2005 and Chief Executive Officer since February 2008 and its Executive Chairman since September 1, 2009. He served as the President of US Oncology Research Inc. Mr. Broussard served as the Chief Executive Officer of US Oncology Inc. since February 1, 2008 and its Chairman of the Board since September 1, 2009. He served as the President of US Oncology Inc. since November 2005 and also served as its Head of Investor Relations. Mr. Broussard led the pharmaceutical distribution business and pharmaceutical services operations and responsible for the development, marketing and growth initiatives of US Oncology. He served as the Chief Financial Officer of US Oncology Holdings, Inc. from November 2005 to July 31, 2006. Mr. Broussard served as the Chief Financial Officer of US Oncology Inc. from August 2000 to July 31, 2006 and served as its Treasurer. He joined US Oncology in August 2000 with primary responsibility for financial and accounting activities, including financial reporting, treasury and taxation. Mr. Broussard served as Principal Accounting Officer of US Oncology Inc. and served as its Executive Vice President, Pharmaceutical Services since 2003. Prior to US Oncology, he served as the Chief Executive Officer of Harbor Dental, from December 1997 to July 2000. From January 1, 1996 to October 1997, he served as an Executive Vice President and Chief Financial Officer of Regency Health Services. From 1993 to 1996, he served as the Chief Financial Officer of Sun Healthcare Group, a healthcare provider. From 1990 to 1993, he served as Vice President and Treasurer for Continental Medical Systems, Inc. He has a wide range of executive leadership experience in publicly traded and private organizations within a variety of healthcare sectors, including oncology, pharmaceuticals, assisted living/senior housing, home care, physician practice management, surgical centers and dental networks. He has been a Director of Humana Inc. since January 01, 2013. He has been a Director of KeyCorp. since May 2015 and serves as a Director of The Healthcare Distribution Management Association. He served as a Director of US Oncology Holdings, Inc. since February 1, 2008 and US Oncology Inc. since February 1, 2008. He served as a Director of US Physical Therapy Inc. from 1999 to November 2011 and Sun Healthcare Group from 1993 to 1996. He is a Certified Public Accountant. Mr. Broussard holds a Bachelor of Business Arts from Texas A&M and an Master in Business Administration from the University of Houston.
CEO Compensation
- Bruce's compensation has been consistent with company performance over the past year.
- Bruce's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Humana management team in years:
- The average tenure for the Humana management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team
Bruce Broussard
President
$16M
56
6.3 yrs
Brian Kane
Chief Financial Officer
$5M
45
4.8 yrs
Tim Huval
Chief Human Resources Officer
$3M
52
6.3 yrs
Jody Bilney
Chief Consumer Officer
$3M
57
6 yrs
William Fleming
Segment President of Healthcare Services
$3M
50
2.1 yrs
Cindy Zipperle
Senior VP & Chief Accounting Officer
55
4.3 yrs
Brian LeClaire
Chief Information Officer
58
5.3 yrs
Amy Smith
Vice President of Investor Relations
Joe Ventura
Chief Legal Officer & Corporate Secretary
41
0.3 yrs
Tom Noland
Senior Vice President of Corporate Communications
19.6 yrs
Board of Directors Tenure
Average tenure and age of the Humana board of directors in years:
- The average tenure for the Humana board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors
Kurt Hilzinger
Chairman of the Board
$544K
57
5.3 yrs
Bruce Broussard
President
$16M
56
6.3 yrs
Frank D'Amelio
Independent Director
$307K
60
15.6 yrs
David Jones
Independent Director
$323K
60
25.9 yrs
Webster Dunbar
Independent Director
$331K
56
14 yrs
Jim O’Brien
Independent Director
$347K
64
13 yrs
Bill McDonald
Independent Director
$323K
61
11.5 yrs
Marissa Peterson
Independent Director
$297K
56
10.7 yrs
Bill Mitchell
Director
$313K
74
10 yrs
David Nash
Director
$306K
63
9.3 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 27. Feb 19 | Sell | Jody Bilney | Individual | 25. Feb 19 | 25. Feb 19 | -2,844 | $307.34 | $-874,061 | ||
| 27. Feb 19 | Sell | Christopher Hunter | Individual | 25. Feb 19 | 25. Feb 19 | -1,146 | $305.24 | $-349,802 | ||
| 26. Feb 19 | Sell | Bruce Broussard | Individual | 22. Feb 19 | 22. Feb 19 | -24,113 | $310.65 | $-7,490,691 | ||
| 21. Feb 19 | Sell | Roy Beveridge | Individual | 19. Feb 19 | 19. Feb 19 | -1,193 | $307.16 | $-366,439 | ||
| 18. Dec 18 | Sell | William Fleming | Individual | 18. Dec 18 | 18. Dec 18 | -1,986 | $295.03 | $-585,921 | ||
| 18. Dec 18 | Sell | Heidi Margulis | Individual | 18. Dec 18 | 18. Dec 18 | -2,437 | $296.22 | $-721,883 | ||
| 13. Nov 18 | Sell | Roy Beveridge | Individual | 08. Nov 18 | 08. Nov 18 | -4,622 | $341.06 | $-1,576,395 | ||
| 12. Sep 18 | Sell | Bruce Broussard | Individual | 10. Sep 18 | 10. Sep 18 | -18,000 | $328.66 | $-5,915,878 | ||
| 17. Aug 18 | Sell | Elizabeth Bierbower | Individual | 16. Aug 18 | 16. Aug 18 | -3,092 | $330.00 | $-1,020,360 | ||
| 06. Aug 18 | Sell | Cynthia Zipperle | Individual | 03. Aug 18 | 03. Aug 18 | -4,886 | $321.89 | $-1,572,747 | ||
| 15. Jun 18 | Sell | Christopher Hunter | Individual | 13. Jun 18 | 13. Jun 18 | -1,635 | $305.99 | $-500,291 | ||
| 14. Jun 18 | Sell | Cynthia Zipperle | Individual | 13. Jun 18 | 13. Jun 18 | -1,000 | $306.01 | $-306,005 | ||
| 12. Jun 18 | Sell | Elizabeth Bierbower | Individual | 11. Jun 18 | 11. Jun 18 | -2,498 | $300.91 | $-751,680 | ||
| 07. May 18 | Sell | Bruce Broussard | Individual | 03. May 18 | 03. May 18 | -8,804 | $286.17 | $-2,519,420 | ||
Management checks
We assess Humana's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Humana has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Should You Be Worried About Insider Transactions At Humana Inc. (NYSE:HUM)?
So shareholders might well want to know whether insiders have been buying or selling shares in Humana Inc. … Over the last year, we note insiders sold 78.26k shares worth US$25m. … It's not particularly great to see insiders were selling shares around current prices
Simply Wall St - – Full articleShould You Think About Buying Humana Inc. (NYSE:HUM) Now?
received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to $312.5 at one point, and dropping to the lows of $268.27. … Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price? … A question to answer is whether Humana's current trading price of $272.6 reflective of the actual value of the?
Simply Wall St - – Full articleWhat Are Analysts Saying About Humana Inc.'s (NYSE:HUM) Growth?
(NYSE:HUM) released its earnings announcement on 31 December 2018, … as a 36% increase in profits is expected in the upcoming year, … the past 5-year average growth rate of 11%.
Simply Wall St - – Full articleWill Humana Inc.'s (NYSE:HUM) Earnings Grow In The Years Ahead?
In December 2018, Humana Inc. … (NYSE:HUM) released its most recent earnings announcement, whicha … showed
Simply Wall St - – Full articleThe Humana Share Price Has Gained 177%, So Why Not Pay It Some Attention?
One flawed but reasonable way to assess how sentiment around a company has changed, is to compare the earnings per share (EPS) with the share price. … During five years of share price growth, Humana achieved compound earnings per share (EPS) growth of 9.4% per year. … This EPS growth is slower than the share price growth of 23% per year, over the same period.
Simply Wall St - – Full articleWhy Humana Inc.’s (NYSE:HUM) Return On Capital Employed Is Impressive
Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. … Return On Capital Employed (ROCE): What is it? … ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business.
Simply Wall St - – Full articleCalculating The Intrinsic Value Of Humana Inc. (NYSE:HUM)
by taking the foreast future cash flows of the company and discounting them back to today's value. … discounted cash flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model
Simply Wall St - – Full articleIs Humana Inc.'s (NYSE:HUM) Stock Available For A Good Price After Accounting For Growth?
(NYSE:HUM) is considered a high growth stock. … However its last closing price of $282.08 left investors wondering whether this growth has already been factored into the share price. … Let’s take a look at some key metrics to determine whether there's any value here for current and potential future investors.
Simply Wall St - – Full articleWhat Humana Inc.'s (NYSE:HUM) ROE Can Tell Us
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … That means that for every $1 worth of shareholders' equity, it generated $0.14 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleIs Now The Time To Look At Buying Humana Inc. (NYSE:HUM)?
saw significant share price movement during recent months on the NYSE, rising to highs of $353.98 and falling to the lows of $274.64. … Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price? … Let’s take a look at Humana’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change
Simply Wall St - – Full articleCompany Info
Description
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health and voluntary insurance benefits; financial protection products; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE South Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2018, the company had approximately 17 million members in medical benefit plans, as well as approximately 6 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Details
| Name: | Humana Inc. |
| HUM | |
| Exchange: | NYSE |
| Founded: | 1961 |
| $32,646,649,806 | |
| 135,637,749 | |
| Website: | http://www.humana.com |
| Address: |
Humana Inc. Humana Building, 500 West Main Street, Louisville, Kentucky, 40202, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NYSE | HUM | Common Stock | New York Stock Exchange | US | USD | 02. Jul 1969 | |
| DB | HUM | Common Stock | Deutsche Boerse AG | DE | EUR | 02. Jul 1969 | |
| LSE | 0J6Z | Common Stock | London Stock Exchange | GB | USD | 02. Jul 1969 | |
| BMV | HUM * | Common Stock | Bolsa Mexicana de Valores | MX | MXN | 02. Jul 1969 |
Number of employees
Current staff
Industry
| Managed Health Care | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/18 23:36 |
| End of day share price update: | 2019/04/18 00:00 |
| Last estimates confirmation: | 2019/04/17 |
| Last earnings filing: | 2019/02/21 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
